We have located links that may give you full text access.
Pharmacological inhibition of mTORC1 but not mTORC2 protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism through Akt and autophagy induction.
Osteoarthritis and Cartilage 2019 Februrary 2
OBJECTIVE: The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that integrates nutrients to execute cell growth. We hypothesized that mTOR is influential in the intervertebral disc-largest avascular, low-nutrient organ. Our objective was to identify the optimal mTOR inhibitor for treating human degenerative disc disease.
DESIGN: mTOR complex 1 (mTORC1) regulates p70/S6K, negatively regulates autophagy, and is controlled by Akt. Akt is controlled by PI3K and mTOR complex 2 (mTORC2). mTORC1 inhibitors-rapamycin, temsirolimus, everolimus, and curcumin, mTORC1&mTORC2 inhibitor-INK-128, PI3K&mTOR inhibitor-NVP-BEZ235, and Akt inhibitor-MK-2206-were applied to human disc nucleus pulposus cells. mTOR signaling, autophagy, apoptosis, senescence, and matrix metabolism were evaluated.
RESULTS: mTORC1 inhibitors decreased p70/S6K but increased Akt phosphorylation, promoted autophagy with LC3-II increases and p62/SQSTM1 decreases, and suppressed pro-inflammatory IL-1β-induced apoptotic TUNEL positivity (versus rapamycin supplementation, 95% CI -0.431--0.194; temsirolimus, -0.529--0.292; everolimus, -0.477--0.241; curcumin, -0.248--0.011) and PARP and caspase-9 cleavage, senescent SA-β-gal positivity (versus rapamycin supplementation, 95% CI -0.437--0.230; temsirolimus, -0.534--0.327; everolimus, -0.485--0.278; curcumin, -0.210 --0.003) and p16/INK4A expression, and catabolic MMP release and activation. Meanwhile, dual mTOR inhibitors decreased p70/S6K and Akt phosphorylation without enhanced autophagy and suppressed apoptosis, senescence, and matrix catabolism. MK-2206 counteracted protective effects of temsirolimus. Additional disc-tissue analysis found relevance of mTOR signaling to degeneration grades.
CONCLUSION: mTORC1 inhibitors-notably temsirolimus with an improved water solubility-but not dual mTOR inhibitors protect against inflammation-induced apoptosis, senescence, and matrix catabolism in human disc cells, which depends on Akt and autophagy induction.
DESIGN: mTOR complex 1 (mTORC1) regulates p70/S6K, negatively regulates autophagy, and is controlled by Akt. Akt is controlled by PI3K and mTOR complex 2 (mTORC2). mTORC1 inhibitors-rapamycin, temsirolimus, everolimus, and curcumin, mTORC1&mTORC2 inhibitor-INK-128, PI3K&mTOR inhibitor-NVP-BEZ235, and Akt inhibitor-MK-2206-were applied to human disc nucleus pulposus cells. mTOR signaling, autophagy, apoptosis, senescence, and matrix metabolism were evaluated.
RESULTS: mTORC1 inhibitors decreased p70/S6K but increased Akt phosphorylation, promoted autophagy with LC3-II increases and p62/SQSTM1 decreases, and suppressed pro-inflammatory IL-1β-induced apoptotic TUNEL positivity (versus rapamycin supplementation, 95% CI -0.431--0.194; temsirolimus, -0.529--0.292; everolimus, -0.477--0.241; curcumin, -0.248--0.011) and PARP and caspase-9 cleavage, senescent SA-β-gal positivity (versus rapamycin supplementation, 95% CI -0.437--0.230; temsirolimus, -0.534--0.327; everolimus, -0.485--0.278; curcumin, -0.210 --0.003) and p16/INK4A expression, and catabolic MMP release and activation. Meanwhile, dual mTOR inhibitors decreased p70/S6K and Akt phosphorylation without enhanced autophagy and suppressed apoptosis, senescence, and matrix catabolism. MK-2206 counteracted protective effects of temsirolimus. Additional disc-tissue analysis found relevance of mTOR signaling to degeneration grades.
CONCLUSION: mTORC1 inhibitors-notably temsirolimus with an improved water solubility-but not dual mTOR inhibitors protect against inflammation-induced apoptosis, senescence, and matrix catabolism in human disc cells, which depends on Akt and autophagy induction.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app